NASDAQ$DNTH
Dianthus Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings ·
Briefing
Dianthus Therapeutics reported Q1 2026 license revenue of $0.5M and net loss of $40.8M, or $(0.85) per share.
Dianthus recognized $0.5 million of license revenue in Q1 2026. Net loss was $40.8 million, or $(0.85) per share, as R&D spending of $34.5 million continued for autoimmune programs following the reverse merger structure.
- License revenue $0.5M.
- Net loss $(40.8)M; loss per share $(0.85).
- R&D $34.5M; G&A $12.5M.
- Post-merger capital structure and reverse split noted.
- Clinical trials advancing for lead candidates.
Headline financials
Revenue & EPS history
Dianthus Therapeutics Inc · Revenue · Quarterly
$6.27M
Forward guidance
Clinical milestones and financing determine runway; no commercial guidance.
Tailwinds
- Partnership license revenue.
- Focused autoimmune pipeline.
Headwinds
- High cash burn.
- Dilution from financing and merger.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q1 2026
+1.6%
Avg return
Earnings day
-2.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
73%
11 / 15 earnings
Positive
+11.1%
Q2 2019
Best reaction
-6.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.1% | -2.9% | -5.8% | |
| Q4 2025 | +9.7% | -1.7% | +15.7% | |
| Q3 2025 | +1.6% | +10.3% | +33.3% | |
| Q2 2025 | -6.1% | -2.4% | +30.0% | |
| Q1 2025 | +2.5% | +0.5% | -7.5% | |
| Q3 2023 | +0.4% | -0.5% | -16.4% | |
| Q2 2023 | +2.5% | -1.2% | -8.6% | |
| Q3 2020 | -0.9% | -1.4% | +11.7% | |
| Q2 2020 | +0.6% | +0.0% | -8.3% | |
| Q1 2020 | +2.7% | -1.3% | +5.4% | |
| Q3 2019 | -2.2% | -13.5% | +21.2% | |
| Q2 2019 | +11.1% | -0.8% | -13.2% | |
| Q1 2019 | +2.7% | +9.9% | -10.7% | |
| Q3 2018 | -3.4% | -24.7% | -14.1% | |
| Q2 2018 | +1.2% | -4.2% | -4.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro